These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 26571495)

  • 1. SS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic Modifier.
    Tamaki S; Fukuta M; Sekiguchi K; Jin Y; Nagata S; Hayakawa K; Hineno S; Okamoto T; Watanabe M; Woltjen K; Ikeya M; Kato T; Toguchida J
    PLoS One; 2015; 10(11):e0142991. PubMed ID: 26571495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma.
    McBride MJ; Pulice JL; Beird HC; Ingram DR; D'Avino AR; Shern JF; Charville GW; Hornick JL; Nakayama RT; Garcia-Rivera EM; Araujo DM; Wang WL; Tsai JW; Yeagley M; Wagner AJ; Futreal PA; Khan J; Lazar AJ; Kadoch C
    Cancer Cell; 2018 Jun; 33(6):1128-1141.e7. PubMed ID: 29861296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer.
    Zöllner SK; Rössig C; Toretsky JA
    Cancer Metastasis Rev; 2015 Sep; 34(3):417-28. PubMed ID: 26277104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of target genes of synovial sarcoma-associated fusion oncoprotein using human pluripotent stem cells.
    Hayakawa K; Ikeya M; Fukuta M; Woltjen K; Tamaki S; Takahara N; Kato T; Sato S; Otsuka T; Toguchida J
    Biochem Biophys Res Commun; 2013 Mar; 432(4):713-9. PubMed ID: 23313505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation.
    de Bruijn DR; Allander SV; van Dijk AH; Willemse MP; Thijssen J; van Groningen JJ; Meltzer PS; van Kessel AG
    Cancer Res; 2006 Oct; 66(19):9474-82. PubMed ID: 17018603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma.
    Kadoch C; Crabtree GR
    Cell; 2013 Mar; 153(1):71-85. PubMed ID: 23540691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.
    Lubieniecka JM; de Bruijn DR; Su L; van Dijk AH; Subramanian S; van de Rijn M; Poulin N; van Kessel AG; Nielsen TO
    Cancer Res; 2008 Jun; 68(11):4303-10. PubMed ID: 18519690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synovial sarcoma is a stem cell malignancy.
    Naka N; Takenaka S; Araki N; Miwa T; Hashimoto N; Yoshioka K; Joyama S; Hamada K; Tsukamoto Y; Tomita Y; Ueda T; Yoshikawa H; Itoh K
    Stem Cells; 2010 Jul; 28(7):1119-31. PubMed ID: 20518020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First cloned human immortalized adipose derived mesenchymal stem-cell line with chimeric SS18-SSX1 gene (SS-iASC).
    Mihály D; Matula Z; Changchien YC; Papp G; Tátrai P; Sápi Z
    Cancer Genet; 2017 Oct; 216-217():52-60. PubMed ID: 29025595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synovial Sarcoma: A Complex Disease with Multifaceted Signaling and Epigenetic Landscapes.
    El Beaino M; Rassy E; Hadid B; Araujo DM; Pavlidis N; Lin PP
    Curr Oncol Rep; 2020 Oct; 22(12):124. PubMed ID: 33025259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diagnostic utility of reduced immunohistochemical expression of SMARCB1 in synovial sarcomas: a validation study.
    Ito J; Asano N; Kawai A; Yoshida A
    Hum Pathol; 2016 Jan; 47(1):32-7. PubMed ID: 26520417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Role for SMARCB1 in Synovial Sarcomagenesis Reveals That SS18-SSX Induces Canonical BAF Destruction.
    Li J; Mulvihill TS; Li L; Barrott JJ; Nelson ML; Wagner L; Lock IC; Pozner A; Lambert SL; Ozenberger BB; Ward MB; Grossmann AH; Liu T; Banito A; Cairns BR; Jones KB
    Cancer Discov; 2021 Oct; 11(10):2620-2637. PubMed ID: 34078620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of Immunohistochemistry With Antibodies to SS18-SSX Chimeric Proteins and C-Terminus of SSX Protein for Synovial Sarcoma Differential Diagnosis.
    Lasota J; Chłopek M; Kaczorowski M; Natálie K; Ryś J; Kopczyński J; Sulaieva O; Michal M; Kruczak A; Harazin-Lechowska A; Szczepaniak M; Koshyk O; Hałoń A; Czapiewski P; Abdullaev Z; Kowalik A; Aldape KD; Michal M; Miettinen M
    Am J Surg Pathol; 2024 Jan; 48(1):97-105. PubMed ID: 37899499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.
    Isfort I; Cyra M; Elges S; Kailayangiri S; Altvater B; Rossig C; Steinestel K; Grünewald I; Huss S; Eßeling E; Mikesch JH; Hafner S; Simmet T; Wozniak A; Schöffski P; Larsson O; Wardelmann E; Trautmann M; Hartmann W
    Clin Cancer Res; 2019 Jun; 25(12):3718-3731. PubMed ID: 30814111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The fusion protein SS18-SSX1 employs core Wnt pathway transcription factors to induce a partial Wnt signature in synovial sarcoma.
    Cironi L; Petricevic T; Fernandes Vieira V; Provero P; Fusco C; Cornaz S; Fregni G; Letovanec I; Aguet M; Stamenkovic I
    Sci Rep; 2016 Feb; 6():22113. PubMed ID: 26905812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth.
    Törnkvist M; Natalishvili N; Xie Y; Girnita A; D'Arcy P; Brodin B; Axelson M; Girnita L
    Biochem Biophys Res Commun; 2008 Apr; 368(3):793-800. PubMed ID: 18267106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanding the Use of an SS18-SSX Antibody for Molecular Assays in Synovial Sarcoma.
    Raquib AR; Hofvander J; Ta M; Nielsen TO
    Appl Immunohistochem Mol Morphol; 2022 Sep; 30(8):531-539. PubMed ID: 35880992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
    Trautmann M; Sievers E; Aretz S; Kindler D; Michels S; Friedrichs N; Renner M; Kirfel J; Steiner S; Huss S; Koch A; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Waha A; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
    Oncogene; 2014 Oct; 33(42):5006-16. PubMed ID: 24166495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of SS18-SSX1 expression in synovial sarcoma by small interfering RNA enhances the focal adhesion pathway and inhibits anchorage-independent growth in vitro and tumor growth in vivo.
    Takenaka S; Naka N; Araki N; Hashimoto N; Ueda T; Yoshioka K; Yoshikawa H; Itoh K
    Int J Oncol; 2010 Apr; 36(4):823-31. PubMed ID: 20198325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Truncated SSX protein suppresses synovial sarcoma cell proliferation by inhibiting the localization of SS18-SSX fusion protein.
    Yoneda Y; Ito S; Kunisada T; Morimoto Y; Kanzaki H; Yoshida A; Shimizu K; Ozaki T; Ouchida M
    PLoS One; 2013; 8(10):e77564. PubMed ID: 24130893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.